GlobeNewswire

Compuware zAdviser Delivers Actionable Analytic Insight to Continuously Improve Quality, Velocity and Efficiency on the Mainframe

Dela

Innovative Machine Learning Helps IT Leaders Pinpoint Opportunities to Boost DevOps Processes and Development Outcomes

 
  • Enterprises dependent on mainframe applications must aggressively improve DevOps quality, velocity and efficiency-even as responsibilities shift to less experienced internal teams and/or outsourcing partners.

  • Compuware is introducing zAdviser, a free product that leverages machine learning to help IT leaders make smarter data-driven decisions to drive continuous improvement of mainframe DevOps.

  • zAdviser identifies patterns that impact quality, velocity and efficiency as they pertain to mainframe development by analyzing a customer's Compuware product usage data and DevOps key performance indicators (KPIs).  

  • zAdviser is fueled by the ongoing collaboration between customers and Compuware, where customers contribute their relevant DevOps data and Compuware contributes their mainframe expertise and machine learning insights.

DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. Based on key performance indicators (KPIs), zAdviser measures application quality, as well as development velocity and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts. zAdviser is free for Compuware customers on current maintenance.

The KPIs were developed based on extensive research with customers and align with those published in the 2018 Forrester report, "Use Four Key Categories To Measure What Matters In Continuous Deployment."

zAdviser leverages a set of analytic models that uncover correlations between mainframe developer behaviors and mainframe DevOps KPIs. These correlations represent the best available empirical evidence regarding the impact of process, training and tooling decisions on digital business outcomes. With this empirical evidence and associated recommendations, managers can make high-impact decisions about their mainframe DevOps methods with vastly improved speed and confidence.

Enterprises that outsource mainframe development can also reap significant value from zAdviser by using the analytical results to continuously achieve better business outcomes over time.

Improvements in mainframe DevOps is an imperative for large enterprises, which are becoming more dependent on mainframe applications-not less. According to a recent Forrester Consulting study commissioned by Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. That percentage is expected to increase to 64 percent by 2019, while at the same time enterprises are failing to replace the expert mainframe workforce they have lost by attrition.

According to the study, "As mainframe workload increases-driven by modern analytics, blockchain and more mobile activity hitting the platform-customer-obsessed companies should seek to modernize application delivery and remove roadblocks to innovation."

The Forrester Consulting study also highlights the importance of responding to these challenges with empirical insight: "KPIs like mean lead time, number of epics per deployment, and metrics that drive automation will harness velocity and efficiency, even as the skills gap of the workforce expands." The full study can be accessed here.

Compuware has been helping their customers qualify, quantify and increase the value derived from their Compuware products through its Value Improvement Program (VIP) for over 15 years. zAdviser is the next step in the evolution of the VIP and evidence-based mainframe process improvement, leveraging these years of experience helping enterprises modernize mainframe DevOps and improve mainframe staff performance.

zAdviser data inputs include both 1) metrics captured from Compuware tools, including behavioral data relating to feature utilization and 2) data captured from the customer's DevOps toolchain.

By aggregating input from customer sites across industries and around the world, Compuware is building the industry's richest repository of mainframe DevOps data-which combined with advanced machine learning methods generates unmatched insight for enterprise IT leaders.

"Our mainframe applications continue to play a critical role in delivering an excellent customer experience," said Steve Kalkowski, Assistant Vice President, The Hartford. "A product like Compuware zAdviser will give us the advanced analytics we need to drive our efforts towards improving developer speed and quality as we transition to an agile delivery model."

Compuware today also announced a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.

"Enterprises cannot afford to be even slightly complacent about the speed and excellence with which they update and evolve the core business logic of their mainframe applications," said Compuware CEO Chris O'Malley. "With zAdviser, Compuware is now offering a powerful, fact-based resource for IT leaders at the world's largest corporations to lead their critical mainframe modernization efforts-and to thereby sustainably derive maximum business value from their investments in mainframe hardware, applications and talent."

To learn more about zAdviser and get involved, visit us here.

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com .

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum